These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 20662951)

  • 21. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL; Lee HY; Low SC; Chan LP; Goh NS; Pang SM
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C; Thomsen HS; Marckmann P
    Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
    Todd DJ; Kagan A; Chibnik LB; Kay J
    Arthritis Rheum; 2007 Oct; 56(10):3433-41. PubMed ID: 17907148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
    Sanyal S; Marckmann P; Scherer S; Abraham JL
    Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis.
    Steger-Hartmann T; Hofmeister R; Ernst R; Pietsch H; Sieber MA; Walter J
    Invest Radiol; 2010 Sep; 45(9):520-8. PubMed ID: 20644486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic systemic fibrosis an unsolved riddle.
    Graziani G; Montanelli A; Brambilla S; Balzarini L
    J Nephrol; 2009; 22(2):203-7. PubMed ID: 19384837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.
    Pietsch H; Raschke M; Ellinger-Ziegelbauer H; Jost G; Walter J; Frenzel T; Lenhard D; Hütter J; Sieber MA
    Invest Radiol; 2011 Jan; 46(1):48-56. PubMed ID: 20938346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.